587 results on '"LIU Yang"'
Search Results
2. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease
3. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
4. Low-dose chidamide restores immune tolerance in ITP in mice and humans
5. Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway
6. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP
7. Bortezomib-Decp Alternating with Daratumumab-Vpd Plus Stem Cell Transplantation, Followed By Maintenance with VP in Ultra-High Risk (UHiR) Newly Diagnosed Multiple Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): A Multicenter, Prospective Phase 2 Pilot Trial (DRAGON CATCHER TRIAL)
8. Targeting the HSP90-MYC-CDK9 Axis to Overcome Dual Resistance to BTK Inhibition and CAR-T Therapy in Mantle Cell Lymphoma
9. CD320 Regulates Bone Marrow Angiogenesis in Multiple Myeloma Via HGF-ERK Axis
10. Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDS
11. Modulating Immunometabolism to Reinvigorate T-Cell Effector Function and Antitumor Immunity in the Mantle Cell Lymphoma Microenvironment
12. HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax
13. Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
14. Outcome of Tandem CD19/CD20 CAR Therapy with 3-Year Follow-up in R/R B-NHL
15. Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay
16. EGFR and HDAC Dual-Target Inhibitor CUDC-101 Enhances the Anti-Myeloma Effects of Bortezomib By Regulating the G2/M Cell Cycle Arrest
17. Siglec-G–CD24 axis controls the severity of graft-versus-host disease in mice
18. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40
19. LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas
20. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
21. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
22. Dopamine signaling regulates hematopoietic stem and progenitor cell function
23. Perioperative Anemia Management in Women Undergoing Gynecologic Procedures: A 10 Year Multisite Study
24. Abemaciclib in Combination with Copanlisib to Overcome Therapeutic Resistance in Mantle Cell Lymphoma
25. Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement
26. Systematic Construction of an Autophagic Risk Model in Bone Marrow for Prognostic Prediction in Multiple Myeloma
27. Single Cell Transcriptomic Profiling of Patient-Derived Xenografts of Mantle Cell Lymphoma Reveals a Special Tumor Cell Population: Seed Cells for Disease Dissemination and Progression
28. Establishment of Patient-Derived Organoid Culture Platform of Mantle Cell Lymphoma
29. Bone Marrow Adipocyte Promotes Epithelial-Mesenchymal-Transition-like Activation in Multiple Myeloma Via CXCL-12/CXCR4 Axis
30. Pirtobrutinib Overcomes Ibrutinib and Venetoclax Resistance in Mantle Cell Lymphoma
31. Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma
32. Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma
33. Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting
34. ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study
35. Bispecific CD19-CD20 and CD19-CD22 CAR-T Cells with Glycogen Synthase Kinase (GSK)-3β Inhibitor TWS119 Treatment Have Superior Therapeutic Effects on Mantle Cell Lymphoma
36. ALKBH5 Functions As an Oncogene in Multiple Myeloma
37. Dynamic Reprogramming and Evolution Associated with Sequential Resistance to Ibrutinib and CAR T Therapy in Mantle Cell Lymphoma
38. A comprehensive RNA editome reveals that edited Azin1 partners with DDX1 to enable hematopoietic stem cell differentiation
39. Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma
40. The Selective CDK9 Inhibitor VIP152 Overcame Therapeutic Resistance in Mantle Cell Lymphoma
41. FABP4 Suppresses the Progress of Multiple Myeloma through Enhancing Alarming Function of Bone Marrow Resident Memory T Lymphocytes
42. Metabolomics-Driven Systematic Research Reveals Different Metabolomic and Lipidomic Profiling of Bone Marrow Plasma in Patients with Multiple Myeloma
43. Applying Machine Learning to Support Early Diagnosis of Light-Chain Amyloidosis: A Combination of Knowledge-Based Approach with Data-Driven Approach
44. The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma
45. Predicting CAR-T Response in Mantle Cell Lymphoma Using Deep Neural Network Models on Single-Cell RNA Sequencing Data
46. Evaluation of Bleeding Self-Assessments By Patients with Immune Thrombocytopenia (ITP): An Agreement Study
47. Exploring BiTE-Integrated CAR T-Cell Therapy to Overcome Tumor Antigen Escape and Reinforce CAR-T Therapy in Mantle Cell Lymphoma
48. Non-Interventional Observational Analysis of the Clinical Outcomes with IO-FIVE (Immune-Oncology Fast In Vivo Efficacy Test) in Lymphoma Patients
49. A Novel Patient-Derived Xenograft Model IO-FIVE for Drug Discovery and Precision Medicine in Lymphoma and Leukemia Patients
50. Dual Targeting of ROR1 and BTK Augments the Anti-Lymphoma Activity in Mantle Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.